EMA has recommended granting a marketing authorisation in the European Union for Foundayo (orforglipron), an oral GLP-1 receptor agonist for weight management and treatment of type 2 diabetes in adults.
EMA has recommended granting a marketing authorisation in the European Union for Foundayo (orforglipron), an oral GLP-1 receptor agonist for weight management and treatment of type 2 diabetes in adults.